Jazz Pharmaceuticals (JAZZ) Stock Statistics & Valuation Metrics

Jazz Pharmaceuticals has a market cap or net worth of $6.72B. The enterprise value is $10.26B.

Jazz Pharmaceuticals has 60,658,810 shares outstanding. The number of shares has decreased by -2.65% in one year.

Jazz Pharmaceuticals’s return on equity (ROE) is 0.14 and return on invested capital (ROIC) is 7.77%.

The current PE Ratio of Jazz Pharmaceuticals is 15.6. Jazz Pharmaceuticals’s PEG ratio is 0.35.

In the last 12 months, Jazz Pharmaceuticals had revenue of 4.07B and earned 560.12M in profits. Earnings per share was 9.06.

In the last 12 months, operating cash flow was 1.32B and capital expenditures -50.92M, giving a free cash flow of 1.27B billion.

Jazz Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Jazz Pharmaceuticals upcoming earnings date is Nov 5, 2025, After Close (Confirmed).

Jazz Pharmaceuticals as a current ratio of 4.46, with Debt / Equity ratio of 29.24%

In the past 12 months, Jazz Pharmaceuticals has paid -91.43M in taxes.

Jazz Pharmaceuticals EV to EBITDA ratio is 8.30, with an EV/FCF ratio of 8.43.

Jazz Pharmaceuticals has $1.19B in cash and marketable securities with $1.08B in debt, giving a net cash position of -$106.30M billion.

Gross margin is 65.97%, with operating margin of 17.61%, and net profit margin of 13.77%.

The average price target for Jazz Pharmaceuticals is $180.27, which is 11.43% higher than the current price. The consensus rating is Strong Buy